FDA Approves Medtronic's Recharge-Free Sacral Nerve Stimulation Therapy For Bladder, Bowel Control
The FDA has approved Medtronic plc's (NYSE:
Benzinga ·
Get all your news in one place.
100's of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100's of premium titles. One news app.
UNCOVERED: 3 | History Defined
10 Biggest Price Target Changes For Tuesday
Needham cut Medtronic plc (NYSE: MDT) price target from $131 to $128. Medtronic shares fell 0.7% to $103.44 in pre-market trading.
Benzinga ·
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Coverage From
Benzinga
StockNews.com
Barchart
MarketBeat
Organisations
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
100+ trusted global sources.
